Federal contractor · WYNANTSKILL, NY

VASCULAR VISION PHARMACEUTICAL CO

No contract obligations recorded for VASCULAR VISION PHARMACEUTICAL CO in FY2026. Since FY2018: $288.9K.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
CZQSE8JMCEN1
Small businessWoman-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 288.9KFY2018
  2. 0FY2019
  3. 0FY2020
  4. 0FY2021

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for VASCULAR VISION PHARMACEUTICAL CO in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

VASCULAR VISION PHARMACEUTICAL CO received $0 in federal assistance in FY2026, on 1 actions (0 new awards).

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2021
$3.1M

Assistance by fiscal year

  1. 0FY2021
  2. 996.2KFY2022
  3. 1MFY2023
  4. 1MFY2024
  5. 0FY2026

Largest awards

  1. SULFATED NON-ANTICOAGULANT HEPARIN NANOPARTICLE (VVP728) FOR SICKLE CELL DISEASE MANAGEMENT - SUMMARY: SICKLE CELL DISEASE (SCD) PRIMARILY…$3.1M
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Sep 23, 2022 – Sep 2, 2026· R44HL147737

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.